{"type":"video","version":"1.0","html":"<iframe src=\"https://www.loom.com/embed/5ee3175f6a1744aabc29e73001d6c916\" frameborder=\"0\" width=\"1920\" height=\"1440\" webkitallowfullscreen mozallowfullscreen allowfullscreen></iframe>","height":1440,"width":1920,"provider_name":"Loom","provider_url":"https://www.loom.com","thumbnail_height":1440,"thumbnail_width":1920,"thumbnail_url":"https://cdn.loom.com/sessions/thumbnails/5ee3175f6a1744aabc29e73001d6c916-a06b516a53e1256e.gif","duration":2779.189,"title":"GLP-1 Prescribing Essentials and Obesity Basics","description":"This Loom provides an overview of prescribing GLP-1s and managing obesity, emphasizing that obesity is a neurohormonal disease driven by hormones and biology rather than willpower. It explains GLP-1 mechanisms including suppression of ghrelin and slowing gastric emptying, notes obesity prevalence of 42% of US adults, and highlights that 95% of patients regain weight within 5 years without continued support. The speaker also stresses licensure protection and legal caution around compounding, specifically advising against research peptides and unverified mixing, and describing key differences such as 503A and 503B pharmacies. Additional discussion covers contraindications like pancreatitis, gastroparesis, pregnancy, and gallbladder disease, plus adherence to FDA titration dosing guidance."}